Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS
Document Type and Number:
WIPO Patent Application WO/2019/199621
Kind Code:
A4
Abstract:
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). The present invention is also directed to pharmaceutical compositions which comprise these bi- functional compounds as well as methods for treating disease states and/or conditions which are mediated through MIF/lgG or where MIF/lgG is a contributing factor to the development and perpetuation of diseases and/or conditions, especially including autoimmune diseases and cancer, among others. The purpose of the present invention is to provide a molecular strategy to lower plasma MIF/lgG level in patients with autoimmune diseases or certain types of cancers. The b.i -functional molecule construct is comprised of a MIF/IgQ-targeting motif, that is derived from small molecule MIF/lgG ligands, and an ASGPr- targeting motif that binds to hepatocyte asialoglycoprotein receptor { ASGPr). The compounds selectively bind MIF or IgG in plasma and subsequently engage the endo-lysosomal pathway of hepatocytes through ASGPr. As a consequence, MIF/igG is internalized and degraded by hepatocytes, thus resulting in potential attenuation of corresponding disease symptoms which are modulated through MIF/igG.

Inventors:
SPIEGEL DAVID (US)
CAIANIELLO DAVID (US)
Application Number:
US2019/026239
Publication Date:
November 14, 2019
Filing Date:
April 08, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV YALE (US)
International Classes:
A61K45/06; A61K31/04; A61K31/351; A61K31/403; A61K31/4192; A61K31/505; A61K31/535; A61K47/55; A61K47/64; A61P29/00; A61P35/00; A61P37/00; C07C205/06; C07D239/26; C07D265/18; C07D309/10; C07D403/04
Attorney, Agent or Firm:
DOYLE, Kathryn et al. (US)
Download PDF:
Claims:
AMENDED CLAIMS

received by the International Bureau on 08 October 2019 (08.10.2019)

AMENDMENTS TO THE CLAIMS

1 A bifunctional compound according to the chemical structure:

wherein:

[MIFBM/IgGBM] is a MIF or IgG Binding Moiety which binds respectively to circulating MIF or IgG in a subject, each of which is related to a disease state and/or condition and is to be removed by action of hepatocytes or other cells of the subject;

[ASGPRBM] is a Binding Moiety which binds to asialoglycoprotein receptors on hepatocytes or other cell receptors, preferably in a subject;

each [CON] is an optional connector chemical moiety which, when present, connects the [LINKER] to [ASGPRBM] and/or to [MIFBM/IgGBM];

[LINKER] is a chemical moiety having a valency from 1 to 15, which covalently attaches to one or more [ASGPRBM] and/or [MIFBM/IgGBM] groups, optionally through a [CON], wherein the [LINKER] optionally itself contains one or more [CON] groups;

k’ is an integer ranging from 1 to 15;

j’ is an integer ranging from 1 to 15;

h and h’ are each independently an integer ranging from 0 to 15;

1L is 0 to 15;

with the proviso that at least one of h, h’, and C is at least 1,

a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

2. The compound according to claim 1, wherein k’, j’, h, h’, and iL are each independently 1, 2, or 3.

3. The compound according to claim 1 or 2, wherein k’ is 1 and wherein j’ is 1, 2, or 3.

4. The compound according to any of claims 1-3: wherein [MIFMB] is a group according to the chemical structure:

wherein:

XM is -(CH2)im- -0-(CH2)im-, -S-(CH2)im-, -NRM-(CH2)IM-, -C(0)-(CH2)im-, a PEG group containing from 1 to 8 ethylene glycol residues or - C(0)(CH2)IMNRM-;

RM is H or C1-C3 alkyl optionally substituted with one or two hydroxyl groups; IM is an integer ranging from 0-6; or wherein [IgGMB] is a group according to the chemical structure:

wherein DNP is 2,4-dinitrophenyl; or wherein [IgGMB] is a group according to the chemical structure:

wherein:

Y’ is H or N02;

X is O, CH2, NR1, S(0), S(0)2, -S(0)20, -0S(0)2, or 0S(0)20; and

R1 is H, C1-C3 alkyl, or -C(0)(Ci-C3 alkyl); or wherein [IgGMB] is a group according to the chemical structure:

wherein R1 is the same as above; and K” is 1-5, or wherein [IgGMB] is a group according to the chemical structure:

wherein:

X’ is CH2, O, N-R1’, or S;

R1 is H or C1-C3 alkyl; and

Z is a bond, a monosaccharide, disaccharide, or oligosaccharide; or wherein [IgGBM] is a group according to the chemical structure:

a-L-Rhamnose b-L-Rhamnose Phosphoryl Choline

Menadione Carboxyethyl Lysine (R1 = Me) wherein:

XR is O, S, or NR1;

XM is O, NR1, or S, and

R1 is H or C1-C3 alkyl; or wherein [IgGBM] is a group according to the chemical structure:

wherein:

X” is O, CH2, NR1, or S; and

R1 is H, C C3 alkyl, or -C(0)(C C3 alkyl);

or

wherein:

Xb is a bond, O, CH2, NR1, or S; and

R1 is the same as above; or wherein [IgGBM] is a group according to the chemical structure:

wherein RN02 is a dinitrophenyl group optionally linked through CH2, S(O), S(0)2, - S(0)20, -0S(0)2, or 0S(0)20; or wherein [IgGBM] is a dinitrophenyl group according to the chemical structure:

wherein:

X is O, CH2, NR1, S(0), S(0)2, -S(0)20, -0S(0)2, or 0S(0)20; and R1 is H, C C3 alkyl, or -C(0)(C C3 alkyl), or wherein [IgGBM] is a 3-indoleacetic acid group according to the chemical structure:

wherein K’” is an integer ranging from 1-4, or wherein [IgGBM] is a group according to a chemical structure as set forth in Figure 67, which is covalently attached to a [CON] group, a [LINKER] group, or an

[ASGPRBM] group, through an amine group optionally substituted with a C1-C3 alkyl group; or wherein [IgGBM] is a peptide selected from the group consisting of:

PAM;

D-PAM;

D-RAM-F;

TWKTSRISIF (SEQ ID NO: l);

FGRLVSSIRY (SEQ ID NO:2);

Fc-III;

FcBP-l;

FcBP-2;

Fc-III-4c;

EPIHRSTLTALL (SEQ ID NO:3);

APAR (SEQ ID NO:4);

FcRM;

HWRGWV (SEQ ID NO:5);

HYFKFD (SEQ ID NO:6);

HFRRHL (SEQ ID NO:7);

HWCitGWV (SEQ ID NO: 8);

D2AAG;

DAAG;

cyclo[(N-Ac)S(A)-RWHYFK-Lact-E] (SEQ ID NO:9);

cy clo [(N -Ac)-Dap(A) -RWHYFK-Lact-E] (SEQ ID NO: 10);

cyclo[Link-M-WFRHYK] (SEQ ID NO: 11);

NKFRGKYK (SEQ ID NO: 12);

NARKFYKG (SEQ ID NO: 13);

FYWHCLDE (SEQ ID NO: 14);

FYCHWALE (SEQ ID NO: 15);

FYCHTIDE (SEQ ID NO: 16);

Dual 1/3; RRGW (SEQ ID NO: 17);

KHRFNKD (SEQ ID NO: 18); or wherein [ASGPRBM] is a group according to the chemical structure:

wherein X is 1-4 atoms in length and comprises O, S, N(Rn1) or C(RN1)(RN1) groups, such that:

when X is 1 atom in length, X is O, S, N(Rn1), or C(RN1)(RN1), when X is 2 atoms in length, no more than 1 atom of X is O, S, or N(Rn1), when X is 3 or 4 atoms in length, no more than 2 atoms of X are O, S, or

N(Rn1);

wherein RN1 is H or C1-C3 alkyl optionally substituted with 1-3 halo groups;

wherein Ri and R3 are each independently H, -(CH2)KOH, -(CH2)KO(CI-C4 alkyl) optionally substituted with 1-3 halo groups, C1-C4 alkyl optionally substituted with 1-3 halo groups, -(CEl2)Kvinyl, -0-(CH2)Kvinyl, - (CH2)Kalkynyl, -(CH2)KCOOH, -(CH2)KC(0)0-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, 0-C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, -C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, or

k 2 - (CH2)K

Ri and R3 are each independently , which is optionally substituted with up to three halo groups; C1-C4 alkyl, each of which alkyl group is optionally substituted with from one to three halo groups or one or two hydroxyl groups; or 0-(Ci-C4 alkyl), each of which alkyl groups is optionally substituted with from one to three halo groups or one or two hydroxyl groups;

Ri and R3 are each independently a group according to the chemical structure: wherein R7 is 0-(Ci-C4 alkyl) optionally substituted with 1 to 3 halo groups or 1-2 hydroxy groups,

Ri and R3 are each independently a group according to the structure:

chemical structure:

Ri and R3 are each independently wherein 8 saturated carbocyclic group;

wherein Rc is absent, H, C1-C4 alkyl optionally substituted with from 1-3 halo groups or 1-2 hydroxyl groups, or a group according to the structure:

wherein R4, R5 and Re are each independently, H, halo, CN, NRN1RN2, - (CH2)KOH, -(CH2)KO(CI-C4 alkyl) optionally substituted with 1-3 halo groups, C1-C3 alkyl optionally substituted with 1-3 halo groups, -0-(Ci-C3- alkyl) optionally substituted with 1-3 halo groups, -(CH2)KCOOH, - (CH2)KC(0)0-(CI-C4 alkyl) optionally substituted with 1-3 halo groups, O- C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, -C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, or

140 wherein

wherein RN , RN1, and RN2 are each independently H or C1-C3 alkyl optionally

substituted with one to three halo groups or one or two hydroxyl groups; wherein K is independently 0, 1, 2, 3, or 4;

wherein K’ is an integer ranging from 1-4;

wherein RN3 is H, or C1-C3 alkyl optionally substituted with 1-3 halo groups or 1-2 hydroxy groups;

wherein RN4 is H, C1-C3 alkyl optionally substituted with 1-3 halo groups or 1-2 hydroxy groups,

LINKERX

wherein is a linker group which comprises at least one [MIFBM/IgGBM] group and links the [MIFBM/IgGBM] group to the [ASGPRBM] through one or more optional [CON] groups, or is a linker group which contains at least one or more functional groups which can be used to covalently bond the linker group to at least one [MIFBM/IgGBM] group or optional [CON] group;

wherein

wherein RAM is H, C1-C4 alkyl optionally substituted with up to 3 halo groups and one or two hydroxyl groups, -(CH2)KCOOH, - (CH2)KC(0)0-(CI-C4 alkyl) optionally substituted with 1-3 halo groups, -0-C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, -C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, -(CH2)K-NRN3RN4; or

141

wherein:

RTA is H, CN, NRN1RN2, -(CH2)KOH, -(CH2)KO(CI-C4 alkyl)

optionally substituted with 1-3 halo groups, C1-C4 alkyl optionally substituted with 1-3 halo groups, -(CH2)KCOOH, - (CH2)KC(0)0-(CI-C4 alkyl) optionally substituted with 1-3 halo groups, -0-C(0)-(Ci-C4 alkyl) optionally substituted with fl-3 halo groups, -C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, or

RTA is a C3-C10 aryl or a three- to ten-membered heteroaryl group containing up to 5 heteroaryl atoms, each of the aryl or heteroaryl groups being optionally substituted with up to three CN, NRN1RN2, -(CH2)KOH, -(CH2)KO(CI-C4 alkyl) optionally substituted with 1-3 halo groups, C1-C3 alkyl optionally substituted with 1-3 halo groups or 1-2 hydroxy groups, -O- (Ci-C3-alkyl) optionally substituted from 1-3 halo groups, - (CH2)KCOOH, -(CH2)KC(0)0-(CI-C4 alkyl) optionally substituted with 1-3 halo groups, 0-C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, or -(CH2)KC(0)- (C1-C4 alkyl) optionally substituted with 1-3 halo groups, or

142 optionally substituted with up to three

C1-C3 alkyl groups which are optionally substituted with up to three halo groups, or

wherein RN, RN1, and RN2 are each independently H or C1-C3 alkyl optionally substituted with one to three halo groups or one or two hydroxyl groups and each -(CH2)K group is optionally substituted with 1-4 C1-C3 alkyl groups which are optionally substituted with 1-3 fluoro groups or 1-2 hydroxyl groups; or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

5. The compound according to any of claims 1-4, wherein the [MIFMB] group is a moiety according to the chemical structure:

wherein:

XM IS -(CH2)im- -0-(CH2)im-, -S-(CH2)im-, -NRM-(CH2)im-, -C(0)-(CH2)im-, a PEG group containing from 1 to 8 ethylene glycol residues, or -C(0)(CH2)iMNRM-;

R\i is H or C1-C3 alkyl optionally substituted with one or two hydroxyl groups; and IM is an integer ranging from 0-6,

or a pharmaceutically acceptable salt or stereoisomer thereof.

6. The compound according to any of claims 1-5, wherein the [ASGPRBM] group is a group according to the chemical structure:

143

wherein X is 1-4 atoms in length and comprises O, S, N(R ) or C(R )(R ) groups, such that:

when X is 1 atom in length, X is O, S, N(Rn1), or C(RN1)(RN1),

when X is 2 atoms in length, no more than 1 atom of X is O, S, or N(Rn1), when X is 3 or 4 atoms in length, no more than 2 atoms of X are O, S, or

N(Rn1);

wherein RN1 is H or C1-C3 alkyl optionally substituted with 1-3 halo groups;

wherein Ri and R3 are each independently H, -(CH2)KOH, -(CH2)KO(CI-C4 alkyl) optionally substituted with 1-3 halo groups, C1-C4 alkyl optionally substituted with 1-3 halo groups, -(CH2)Kvinyl, -0-(CH2)Kvinyl, - (CH2)Kalkynyl, -(CH2)KCOOH, -(CH2)KC(0)0-(C1-C4 alkyl) optionally substituted with 1-3 halo groups, 0-C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, -C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, or

Ri and R3 are each independently — )— (CH2)K— I—

, which is optionally substituted with up to three halo groups; C1-C4 alkyl, each of which alkyl group is optionally substituted with from one to three halo groups or one or two hydroxyl groups; or 0-(Ci-C4 alkyl), each of which alkyl groups is optionally substituted with from one to three halo groups or one or two hydroxyl groups;

Ri and R3 are each independently a group according to the chemical structure: wherein R7 is 0-(Ci-C4 alkyl) optionally substituted with 1 to 3 halo groups or 1-2 hydroxy groups, -

NRN - (CH2)K - /¾ .

3RN4, or (CH2)K - O or

Ri and R3 are each independently a group according to the structure: chemical structure:

146

CARBOCYCLIC

<CH2)Kf- ll INKFRxi

Ri and R3 are each independently , wherein

CARBOCYCLIC

is a C3-C8 saturated carbocyclic group;

wherein Rc is absent, H, C1-C4 alkyl optionally substituted with from 1-3 halo groups or 1-2 hydroxyl groups, or a group according to the structure:

wherein R4, R5 and Re are each independently, H, halo, CN, NRN1RN2, - (CH2)KOH, -(CH2)KO(CI-C4 alkyl) optionally substituted with 1-3 halo groups, C1-C3 alkyl optionally substituted with 1-3 halo groups, -0-(Ci-C3- alkyl) optionally substituted with 1-3 halo groups, -(CH2)KCOOH, - (CH2)KC(0)0-(CI-C4 alkyl) optionally substituted with 1-3 halo groups, O- C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, -C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, or

wherein

wherein RN , RN1, and RN2 are each independently H or C1-C3 alkyl optionally

substituted with one to three halo groups or one or two hydroxyl groups;

147 wherein K is independently 0, 1, 2, 3, or 4;

wherein K’ is an integer ranging from 1-4;

wherein RN3 is H, or C1-C3 alkyl optionally substituted with 1-3 halo groups or 1-2 hydroxy groups;

wherein RN4 is H, C1-C3 alkyl optionally substituted with 1-3 halo groups or 1-2 hydroxy groups,

LINKERX

wherein is a linker group which comprises at least one [MIFBM/IgGBM] group and links the [MIFBM/IgGBM] group to the [ASGPRBM] through one or more optional [CON] groups, or is a linker group which contains at least one or more functional groups which can be used to covalently bond the linker group to at least one [MIFBM/IgGBM] group or optional [CON] group;

wherein

wherein RAM is H, C1-C4 alkyl optionally substituted with up to 3 halo groups and one or two hydroxyl groups, -(CH2)KCOOH, - (CH2)KC(0)0-(CI-C4 alkyl) optionally substituted with 1-3 halo groups, -0-C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, -C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, -(CH2)K-NRN3RN4; or

wherein:

RTA is H, CN, NRN1RN2, -(CH2)KOH, -(CH2)KO(C1-C4 alkyl)

optionally substituted with 1-3 halo groups, C1-C4 alkyl optionally substituted with 1-3 halo groups, -(CH2)KCOOH, - (CH2)KC(0)0-(CI-C4 alkyl) optionally substituted with 1-3 halo groups, -0-C(0)-(Ci-C4 alkyl) optionally substituted with fl-3 halo groups, -C(0)-(Ci-C4 alkyl) optionally substituted

148 with 1-3 halo groups, or

RTA is a C3-C10 aryl or a three- to ten-membered heteroaryl group containing up to 5 heteroaryl atoms, each of the aryl or heteroaryl groups being optionally substituted with up to three CN, NRN1RN2, -(CH2)KOH, -(CH2)KO(C1-C4 alkyl) optionally substituted with 1-3 halo groups, C1-C3 alkyl optionally substituted with 1-3 halo groups or 1-2 hydroxy groups, -O- (Ci-C3-alkyl) optionally substituted from 1-3 halo groups, - (CH2)KCOOH, -(CH2)KC(0)0-(CI-C4 alkyl) optionally substituted with 1-3 halo groups, 0-C(0)-(Ci-C4 alkyl) optionally substituted with 1-3 halo groups, or -(CH2)KC(0)- (Ci-C4 alkyl) optionally substituted with 1-3 halo groups, or

optionally substituted with up to three

C1-C3 alkyl groups which are optionally substituted with up to three halo groups, or

wherein RN, RN1, and RN2 are each independently H or C1-C3 alkyl optionally substituted with one to three halo groups or one or two hydroxyl groups and each -(CH2)K group is optionally

149 substituted with 1-4 C1-C3 alkyl groups which are optionally substituted with 1-3 fluoro groups or 1-2 hydroxyl groups; or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

7. The compound according to claim 4 or 6, wherein:

X in [ASGPRBM] is -0-C(RN1)(RN1)-, -C(RN1)(RN1)-0-, -S-C(RN1)(RN1)-, -C(RN1)(RN1)-S-, - N(RN1)-C(RN1)(Rn1)-, -C(RN1)(RN1)-N(Rn1)-, or -C(RN1)(RN1)-C(RN1)(RN1)-, when X is 2 atoms in length,

X in [ASGPRBM] is -0-C(RN1)(RN1)-C(RN1)(RN1)-, -C(RN1)(RN1)-0-C(RN1)(RN1)-, -O- C(RN1)(RN1)_O_ -0-C(RN1)(RN1)-S-, -0-C(RN1)(RN1)-N(Rn1)-, -S-C(RN1)(RN1)- C(RN1)(RN1)-, -C(RN1)(RN1)-S-C(RN1)(RN1)-, -C(RN1)(RN1)-C(RN1)(RN1)-S, -S- C(RN1)(RN1)-S- -S-C(RN1)(RN1)-0-, -S-C(RN1)(RN1)-N(Rn1)-, -N(RN1)-C(RN1)(Rn1)- C(RN1)(RN1)-, -C(RN1)(RN1)-N(RN1)-C(RN1)(Rn1)-, -C(RN1)(RN1)-C(RN1)(RN1)-N(Rn1)- , -N(RN 1)-C(RN1)(RN1)-N(Rn1)-, or -C(RN1)(RN1)-C(RN1)(RN1)- C(RN1)(Rn1), when X is 3 atoms in length, and

X in [ASGPRBM] is -0-C(RN1)(RN1)-C(RN1)(RN1)-C(RN1)(RN1)-, -C(RN1)(RN1)-0- C(RN1)(RN1)-C(RN1)(RN1)-, -0-C(RN1)(RN1)-0-C(RN1)(RN1)-, -S-C(RN1)(RN1)- C(RN1)(RN1)-C(RN1)(RN1)-, -C(RN1)(RN1)-S-C(RN1)(RN1)-C(RN1)(RN1)-, -C(RN1)(RN1)- C(RN1)(RN1)-S-C(RN1)(RN 1)-, -S-C(RN1)(RN1)-S-C(RN1)(RN1)-, -N(RN1)-C(RN1)(Rn1)- C(RN1)(RN1)- C(RN1)(RN1)-, or -C(RN1)(RN1)-N(RN1)-C(RN1)(RN1)-C(RN1)(Rn1)-, when X is 4 atoms in length.

8. The compound according to claim 4 or 6, wherein X is OCH2 or CH20 and wherein

RN1 is H.

9. The compound according to claim 5, wherein XM is a PEG group containing from 1 to

8 ethylene glycol residues.

10. The compound according to claim 5, wherein XM is -C(0)-(CH2)IM- and wherein IM is 1, 2, or 3.

11. The compound according to claim 4 or 6, wherein the [ASGPRBM] group is a group according to the chemical structure:

150

or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

12. The compound according to claim 4, wherein the [ASGPRBM] group is a group according to the chemical structure:

wherein:

RA is C1-C3 alkyl optionally substituted with 1-5 halo groups;

ZA IS -(CH2)im-. -0-(CH2)im-, -S-(CH2)im-, -NRM-(CH2)im- -C(0)-(CH2)im-, a PEG group containing from 1 to 8 ethylene glycol residues, or -C(0)(CH2)IMNRM-; and

ZB IS absent, -(CH2)IM-, -C(0)-(CH2)im-, or -C(0)-(CH2)IM-NRM-.

13. The compound according to claim 12, wherein RA is a methyl or ethyl group which is optionally substituted with 1-3 fluoro groups.

14. The compound according to claim 12, wherein ZA is a PEG group containing from 1 to 4 ethylene glycol residues.

15. The compound according to claim 12, wherein the methyl or ethyl group is substituted with 1-3 fluoro groups.

16. The compound according to any of claims 4 and 6-15, wherein Ri and R3 are each independently a group according to the chemical structure:

151

17. The compound according to any of claims 4 and 6-15, wherein Ri and R3 of the [ASGPRBM] group are each independently a moiety of Figure 68.

18. The compound of any of claims 4 and 6, where R2 of the [ASGPRBM] group is a moiety of Figure 69.

19. The compound of any of claims 4 and 6-18, wherein the [IgGBM] is a group according to the chemical structure:

where K’” is an integer ranging from 1-4.

20. The compound of any of claims 4 and 6-18, wherein the [IgGBM] group is a peptide moiety according to the chemical structure:

152

21. The compound according any of claims 1-20, wherein the linker is a

polyethyleneglycol containing linker having from 1 to 12 ethylene glycol residues.

22. The compound according to any of claims 1-20, wherein the linker is a linker according to the chemical structure:

or a polypropylene glycol or polypropylene-co-polyethylene glycol linker containing between 1 and 100 alkylene glycol units;

wherein Ra is H, C1-C3 alkyl or alkanol or forms a cyclic ring with R3 to form a pyrrolidine or hydroxypyrroline group and R3 is a side chain derived from a D- or L amino acid selected from the group consisting of alanine (methyl), arginine (propyleneguanidine), asparagine (methylenecarboxy amide), aspartic acid (ethanoic acid), cysteine (thiol, reduced or oxidized di-thiol), glutamine (ethylcarboxyamide), glutamic acid

(propanoic acid), glycine (H), histidine (methyleneimidazole), isoleucine (1- methylpropane), leucine (2-methylpropane), lysine (butyleneamine), methionine (ethylmethylthioether), phenylalanine (benzyl), proline, hydroxyproline (R3 forms a

153 cyclic ring with R;, and the adjacent nitrogen group to form a pyrrolidine or hydroxypyrrolidine group), serine (methanol), threonine (ethanol, 1 -hydroxy ethane), tryptophan (methyleneindole), tyrosine (methylene phenol) or valine (isopropyl); and m is an integer ranging from 1 to 15.

23. The compound according to any of claims 1-20, wherein the linker is a group according to the chemical structure:

wherein:

Ram is H or C1-C3 alkyl optionally substituted with one or two hydroxyl groups; na is 1-15; and

m is an integer ranging from 1 to 100.

24. A compound according to any of claims 1-20, wherein the linker is a group according to the chemical formula:

wherein:

Z and Z’ are each independently a bond, -(CH2)i-0-, -(CH2)i-S-, -(CH2)i-N(R)-,

wherein the -(CH2), group, if present in Z or Z’ , is bonded to a connector group [CON], [MIFBM]/[IgGBM] or [ASGPRBM];

each R is H, or C1-C3 alkyl or alkanol;

each R2 is independently H or C1-C3 alkyl;

154 each Y is independently a bond, O, S, or N-R;

each i is independently 0 to 100;

bond, with the proviso that Z, Z’ and D are not each simultaneously bonds; j is an integer ranging from 1 to 100;

m’ is an integer ranging from 1 to 100;

n is an integer ranging from 1 to 100;

X1 is O, S, or N-R; and

R is H, or C1-C3 alkyl or alkanol.

25. The compound according to any of claims 1-20, wherein the linker is or comprises a group according to the chemical structure:

wherein each n and n’ is independently 1 to 25; and each n” is independently 0 to 8.

26. The compound according to any of claims 1-20, wherein the linker is a group represented by the chemical formula:

PEG-[CON]-PEG

wherein each PEG is independently a polyethylene glycol group containing from 1-12

ethylene glycol residues and [CON] is a triazole group

27. The compound according to any of claims 1-25, wherein: the [CON] is a group according to the structure:

155

wherein RC0N1 and RC0N2 are each independently H, methyl, a bond (for attachment to another moiety); or a diamide group according to the structure:

wherein:

X2 is CH2, O, S, NR4, C(0), S(0), S(0)2, -S(0)20, -0S(0)2, or 0S(0)20; X3 is O, S, or NR4;

156 R4 is H, C C3 alkyl or alkanol, or -C(0)(C C3 alkyl);

R1 is H or Ci-C3 alkyl; and

n” is independently an integer ranging from 0 to 8; or the [CON] is a group according to the chemical structure:

wherein R1C0N, R2C0N. and R3C0N are each independently H, -(CH2)MCI-, -

(CH2)MClaC(0)xA(NR4)xA-(CH2)MCla-,-(CH2)MCla(NR4)xAC(0)xA-(CH2)MCla-, or -(CH2)MCiaO-(CH2)MCi-C(0)NR4-, with the proviso that R1C0N, R2C0N and R3C0N are not simultaneously H;

each MC1 is independently an integer ranging from 1-4;

each MCla is independently an integer ranging from 0-4;

each XA is 0 or 1 ; and

R4 is H, C C3 alkyl or alkanol, or -C(0)(C C3 alkyl),

with the proviso that MCla and XA in a moiety are not all simultaneously 0.

28. The compound according to any of claims 1-25, wherein the [CON] is a group according to the chemical structure:

29. A compound as set forth in any of Figures 1, 7, 13 and 16-66 hereof.

157

30. (cancelled)

31. The compound according to any of claims 1-4, which is MIF-NVS-PEGnGN3, MIFGN3, MIF-PEGnGN3, MIF-CF3-1, MIF-CF3-2 or MIF-CF3-3.

32. The compound according to any of claims 1-4, which is MIF-GN3, MIF-AcF2, MIF- AcF3, MIF-AcF2-3, MIF-AcF3-2. MIF-AcF3-3, MIF-Ac-3, MIF-Et-3, MIF-EtF3-3, MIF- AcF, MIF-AcF-2, MIF-AcF-3, MIF-AcF2-2, MIF-Ac, MIF-Ac-2, MIF-Et, MIF-Et-2, MIF- EtF3, or MIF-EtF3-2.

33. A pharmaceutical composition comprising an effective amount of a compound according to any of claims 1-32 in combination with a pharmaceutically acceptable carrier, additive, or excipient.

34. The composition according to claim 33, which further includes an additional bioactive agent effective to treat cancer, autoimmune disease, and/or inflammatory disease in the patient or subject or which is associated with the upregulation of MIF or IgG in the patient or subject.

35. The composition according to claim 33 or 34, which is adapted for treating cancer in a patient.

36. The composition according to claim 33, which further includes an anticancer agent.

37. The composition according to claim 36, wherein the additional anticancer agent is everolimus, irabeciedin, abraxane, TLK 286, AV-299, DN-101 , pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1 152, enzastaunn, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGF TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bel-2 inhibitor, an HDAC inhbitor, a c-MET inhibitor, a PAR? inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an 1GFR-TK inhibitor, an anti-HGF antibody, a P13 kinase inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint- 1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (rnek) inhibitor, aVEGF

158 trap antibody, pemetrexecl, eriotimb, dasatanib, nilotmib, decatanib, pamtumumab,

amrubicin, oregovomab, Lep-etu, nolatrexed, azd217 l, haiabulin, ofatumumab (Arzerra), zanoliraumab, edotecarin, tetrandrine, rubitecan tesmilifene, oblimersen, ticilitnumab, ipilimumab, gossypol. Bio 11 1 , 131-I-TM-601 , ALT- 110, BIO 140, C€ 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001 , IPdRi KRX-0402, lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311 , romidepsin, ADS- 100380, sumlinib, 5-fluorouracil, vonnostar, etoposide, gemcitabine, doxombicin, irinotecan, Uposomal doxombicin, 5’-deoxy-5-fluorouridine, vincristine, temozolornide, ZK.-304709, sdicxciib; PD0325901, AZD-6244, capecitabine, L -Glutamic acid, -j4-{2-(2-amino-4,7- dihydro-4-oxo-l H - pyrrolo[2,3- d ]pyri idin-.5-yl)ethy3]benzoyl]-, disodium salt, hepiahydrate, camptodieein, PEG-1 abeled irinotecan, tamoxifen, toremifene citrate, anastrazoie, exemestane, ietrozole, DES(dietliylstilbestroi), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-lCl 1 , CHIR-258,); 3-[5-(raetbylsuifonylpiperadinernethyl)- indolylj-quinolone, vatalanib, AG-013736, AVE-0005, the acetate salt of [D- SeriBu t ) 6 ,Azgly 10 j (pyro-Glu-Iiis-Trp-Ser-Tyr-D-Ser(Bu t )-Leu-Atg-Pro- Azgly-NH acetate

[CMHMNMOU -(CiHfOiix where ::: 1 to 2.4], goserelin acetate, leuprolide acetate, triptorebn pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-

165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-

166, GW-572016, ionafamib, BMS-214662, tipifamib; amifostine. NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, triehostatin A. FK-228, SU11248 sorafenib,

K.R.N951 , aminoglutethimide, amsacrine, anagrelide, L-asparaginase, Bacillus Calmette- Guerin (BCG) vaccine, bleomycin, buserelin, busulfan, carboplatin, carmustme,

chloraxnbucil, cisplatin, cladribine, clodronate, eyproterone, eytarabine, daearbazine, dactinomycm, daunombicm, dietbylstilbestrol epirubicin fludarabine, fludrocortisone, fluoxymesterone, flutamide, gemcitabine, gleevac, hydroxyurea, idaxubicin, ifosfamide, imatinib, leuprolide, levamisoie, lomustme, mechloretiiamine, melphalan, 6-xnercaptopurine, mesna, methotrexate, mitomycin, mrtotane. mitoxantrone, nilutamide, octreotide, oxalipSatm, pamidronate, peniostatin, plicamycin, porfimer, procarbazine, raltitrexed, riiuximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vmdesine, 13-cis~retinoic acid, phenylalanine mustard, uracil mustard, estramustine, aitretamine, floxuridine, 5-deooxyundine, cytosine arahinoside, 6-mecaptopurine, deoxycoformycin, calcitnol, valmbicin, mithramycin, vinblastine, vmorelbme, topotecan, razoxin, manmastat.

159 COL-3, neovastat, BMS-275291, squaiamine, endostatin, SU5416, SU6668, EMD121974, interleukin- 12, IM862, angiostatin, vitaxin, droioxifene, idoxyfene, spironolactone, finasteride, cimiti ine, trastuzumab, denileukin diftitox,gefitinib, bortezimib, paclitaxel, irinotecan, topotecan, doxorubicin, docetaxel, vinorelbine, bevacizumab, erbitux, cremophor- free paclitaxel, epithilone B, BMS- 247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA- 923, arzoxifene, f ilvestrant, acolbifene, lasofoxifene, idoxifene, TSE- 424, HMR- 3339, ZK186619, PTK787/ZK 222584, VX-745, PD 184352, rapamycin, 40-0- (2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L- 779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab,

hydrocortisone, interleukin- 11 , dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard,

methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-l receptor antagonists, palonosetron, aprepitant, diphenhydramine, hydroxyzine,

metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa and darbepoetin alfa, vemurafenib, immunotherapy agents PDL1 inhibitors, PD1 inhibitors, or CTLA-4 inhibitors.

38. A method of removing excess circulating MIF or IgG in a patient or subject, the method comprising administering to the patient or subject an effective amount of a compound according to any of claims 1-32.

39. A method of treating a disease state and/or condition which is associated with the upregulation of MIF or IgG in a patient or subject, the method comprising administering to the patient or subject an effective amount of a compound according to any of claims 1-32.

40. The method according to claim 39, wherein the disease state and/or condition is

160 cancer, an autoimmune disease, or an inflammatory disease.

41. A method of treating cancer in a subject or patient, the method comprising administering to the subject or patient an effective amount of a composition according to any of claims 33-37.

42. A method of treating an autoimmune disease in a subject or patient, the method comprising administering to the subject or patient an effective amount of a composition according to any of claims 33-34 to the subject or patient.

43. A method of treating an inflammatory disease in a subject or patient, the method comprising administering to the subject or patient an effective amount of a composition according to any of claims 33-34 to the subject or patient.

161